



Research Article

Copy Right@ Dr. Bin Zhao

# Biomathematical Analysis on Impedance Measurement During COVID-19 Pandemic

Bin Zhao<sup>1\*</sup> and Xia Jiang<sup>2</sup>

<sup>1</sup>School of Science, Hubei University of Technology, China

<sup>2</sup>Hospital, Hubei University of Technology, China

\*Corresponding author: Dr. Bin Zhao, School of Science, Hubei University of Technology, Wuhan, Hubei, China.

To Cite This Article: Bin Z, Xia J. Biomathematical Analysis on Impedance Measurement During COVID-19 Pandemic. Am J Biomed Sci & Res. 2022 7(3) AJBSR.MS.ID.002360, DOI: 10.34297/AJBSR.2022.17.002360

Received: 📅 October 29, 2022; Published: 📅 November 22, 2022

## Abstract

The coating impedance size can reflect the aging degree of the coating to a certain extent; therefore, the measurement of the coating impedance size can monitor the aging degree of the coating in real time. Since the coating is traditionally considered as an insulating medium, its impedance value before aging is as high as  $10^8\Omega$  or more, it is difficult to achieve accurate impedance measurement, and the current generated by loading by voltammetry at low voltage is very weak and easily affected by external electromagnetic interference noise, and the measurement accuracy is low. In this paper, by pluralizing the high impedance, establishing the mathematical model of differential amplification circuit, and then using sinusoidal fitting in which processing, so that the obtained signal is more accurate during COVID-19 pandemic.

**Keywords:** High impedance measurements, Differential circuits, Sine fitting

## Introduction

In the industrial field, impedance is an important parameter, and the measurement and analysis of impedance helps us to understand the changes of morphological characteristics of the object under test [1]. For example, in the oil and gas pipeline transmission system, the impedance of the pipeline corrosion protection layer needs to be measured to grasp its service life [2] in the field of biomedicine, the clinical application of bioimpedance technology has a great front [3] in the field of corrosion monitoring, the monitoring of aircraft coatings, which is an effective means to prevent corrosion of the base metal[4] these belong to the category of high impedance measurement, with an impedance of up to  $10^8\Omega$ . Therefore, in the processing of these weak signals processing, the idea of sinusoidal fitting is used to process to obtain more information during COVID-19 pandemic [5].

## Differential Amplifier Circuit Mathematical Model

The excitation signal is formed by bucking the sine signal generated by filtering, assuming that the bucking scale factor is

$k_1$  and the amplitude of the sine signal before bucking is  $A$ , the excitation signal is expressed as [6,7]:

$$V_i(t) = k_1 A \sin(\omega t) \quad (1)$$

If the differential amplification is  $K_2$ , the output  $V_o$  of the differential amplifier circuit and the input  $V_i$  satisfy the following vector relationship [8,9]:

$$\dot{V}_o = \frac{k_2 Z_x}{Z_x + Z_o} \dot{V}_i \quad (2)$$

Translated into a specific functional form of time it can be expressed as [10-12]:

$$V_o(t) = \frac{k_1 k_2 |Z_x|}{|Z_x + Z_o|} \sin(\omega t + \varphi) \quad (3)$$

$Z_o$ : Reference impedance, standard resistance is generally used in measurement circuits.



$\varphi$ : Difference between  $Z_x$  and the impedance angle of  $Z_x + Z_0$ .

If the presence of the input capacitance  $C_0$  of the amplified input system is not considered,  $Z_x$  is the measured coating complex impedance  $Z_c$ , and if the presence of the input capacitance is considered, it is the combined impedance of the coating complex impedance in parallel with the capacitance, satisfying the following relationship [13-15].

$$Z_x = \frac{Z_c}{1 + j\omega C_0 Z_c} \quad (4)$$

Table 1: Sequence table.

Sequence	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Value	3	5	3	7	7	10	9	6	8	5	2	1	3	6	7

If a moving average with a window of 5 is used, the element with a sequence of 11 and a value of 2 should be replaced with [16,17].

$$p11 = (8 + 5 + 2 + 1 + 3) / 5 \quad (6)$$

Then the element with a sequence of 12 and a value of 1 should be replaced with

$$p12 = (5 + 2 + 1 + 3 + 6) / 5 \quad (7)$$

For fast calculation, the following formula can be used for recursion

$$p12 = (5 * p11 + 6 - 8) / 5 \quad (8)$$

The complex impedance of the coating under test is:

$$Z_c = \frac{Z_x}{1 - j\omega C_0 Z_x} \quad (5)$$

### Understanding of Sine Fitting

**Simple moving average method:** First, we use the simple moving average method to feel the meaning of "moving". There is a sequence as follows (Table 1).

Simple moving average is defined as: Simple moving average of data  $P_1, P_2, \dots, P_M$  with window  $n$ :

$$\bar{P}_{SM} = \frac{P_M + P_{M-1} + \dots + P_{M-(N-1)}}{n} = \frac{1}{n} \sum_{i=0}^{n-1} P_{M-i} \quad (9)$$

The iteration form is:

$$\bar{P}_{SM} = \bar{P}_{SM,prev} + \frac{P_M}{n} - \frac{P_M - N}{n} \quad (10)$$

In MATLAB, there is a corresponding smooth function available. We can use *matlab* to verify smooth ( $y, span$ ). The following figure shows the result of  $data2 = \text{smooth}(data1, 5)$  (Figure 1).




Figure 1: Smooth validation chart.

**Digital Sine Fitting:** We can draw the following discrete curve by inputting the following commands in the *matlab* command line window [18].

```
>> i = 0:100;
>> y = 2 * cos(2 * pi * i ./ 25 + pi / 4) + 3;
>> plot(i, y);
```

(Figure 2) If each point of the above discrete curve is defined by

$$x_i = A \cos(\theta + \Delta_i) + \varepsilon_i + c \quad (11)$$

Then there is

$$\begin{cases} A = 2 \\ \theta = \pi/4 \\ \Delta_i = i * (2\pi/25) \\ \varepsilon_i = 0 \\ C = 3 \end{cases} \quad (12)$$




Figure 2: Discrete curve chart.

Since the known curve is drawn, the above parameters can be easily obtained, and the error of each point is 0. However, for a relatively disordered sequence, there will always be a certain deviation from the ideal curve, so the error will not be 0, but our

purpose is to find a curve that is closest to it, and the evaluation standard is the sum of squares of errors, which is consistent with the least square method. (Figure 3) The following diagram shows a discrete sequence of approximate cosine curves [19].




Figure 3: Discrete sequences.

Similarly, we use the following expression

$$x_i = A \cos(\theta + \Delta_i) + \varepsilon_i + c \quad (13)$$

For subsequent operation processing, another form is used to express

$$x_i = a \cos \Delta_i + b \sin \Delta_i + c + \varepsilon_i \quad (14)$$

Among,

$$\begin{cases} A = \sqrt{a^2 + b^2} \\ \theta = a \tan 2(-b, a) \end{cases} \quad (15)$$

So, we think that  $x_i = a \cos \Delta_i + b \sin \Delta_i + c$  is the function that can best represent the discrete curve in the above figure, but a, B and C are temporarily unknown. Define the sum of squares of errors as

$$f(a, b, c)_{\min} = \sum \varepsilon_i^2 = \sum [x_i - (a \cos \Delta_i + b \sin \Delta_i + c)]^2 \quad (16)$$

In order to find the A, B and C that minimize the above formula, the partial derivatives of a, b and c in the above formula are obtained, and the partial derivatives are zero, then

$$\text{Sorted: } \begin{cases} \frac{\partial f}{\partial a} = 2 \sum \cos \Delta_i [x_i - (a \cos \Delta_i + b \sin \Delta_i + c)] = 0 \\ \frac{\partial f}{\partial b} = 2 \sum \sin \Delta_i [x_i - (a \cos \Delta_i + b \sin \Delta_i + c)] = 0 \\ \frac{\partial f}{\partial c} = 2 \sum [x_i - (a \cos \Delta_i + b \sin \Delta_i + c)] = 0 \end{cases} \quad (17)$$

$$\begin{cases} a \cdot \sum \cos^2 \Delta_i + b \cdot \sum \sin \Delta_i \cos \Delta_i + c \cdot \sum \cos \Delta_i = \sum x_i \cdot \cos \Delta_i \\ a \cdot \sum \sin \Delta_i \cos \Delta_i + b \cdot \sum \sin^2 \Delta_i + c \cdot \sum \sin \Delta_i = \sum x_i \cdot \sin \Delta_i \\ a \cdot \sum \cos \Delta_i + b \cdot \sum \sin \Delta_i + c \cdot \sum 1 = \sum x_i \end{cases} \quad (18)$$

The values of a, b and c are:

$$\begin{bmatrix} \sum \cos^2 \Delta_i & \sum \sin \Delta_i \cos \Delta_i & \sum \cos \Delta_i \\ \sum \sin \Delta_i \cos \Delta_i & \sum \sin^2 \Delta_i & \sum \sin \Delta_i \\ \sum \cos \Delta_i & \sum \sin \Delta_i & \sum 1 \end{bmatrix}^{-1} \begin{bmatrix} \sum x_i \cdot \cos \Delta_i \\ \sum x_i \cdot \sin \Delta_i \\ \sum x_i \end{bmatrix} \quad (19)$$

We generally use the whole period fitting. For the whole period

$$\begin{bmatrix} a \\ b \\ c \end{bmatrix} = \begin{bmatrix} -2 \sum x_i \sin \Delta_i / n \\ 2 \sum x_i \cos \Delta_i / n \\ \sum x_i / n \end{bmatrix} \quad (20)$$

After getting a and b, of course, you can also know the parameter A and  $\theta_0$

**Moving Sine Fitting**

For ease of understanding, only the whole cycle is described here. Using the method in 2.2, perform sine fitting on the interval  $Z_i$  (corresponding to the moving average window, which contains exactly one cycle, assuming that the number of cycle points is n) where the element  $X_i$  is located. a, b, and c can be obtained, and only  $a_i, b_i, c_i$  of element  $x_i$  are obtained. Can also get  $A_i, \theta_i$  (Figure 4).




Figure 4: Four-period discrete series.

So, Then, the interval  $Z_{i+1}$  of element  $X_{i+1}$  is sinusoidally fitted to obtain  $a_{i+1}, b_{i+1}, c_{i+1}$  of element  $x_{i+1}$ , and also  $A_{i+1}$  and  $\theta_{i+1}$ .

In fact, for the convenience of calculation, the calculation formulas of a, b and c in 2.2 are combined. It can be inferred that [20].

$$\begin{bmatrix} a_{i+1} \\ b_{i+1} \\ c_{i+1} \end{bmatrix} = \begin{bmatrix} (n * a_i + 2x_i - [n/2] \sin \Delta_i - [n/2] - 2x_i + [n/2] + 1 \sin \Delta_i + [n/2] + 1) / n \\ (n * b_i - 2x_i - [n/2] \cos \Delta_i - [n/2] + 2x_i + [n/2] + 1 \cos \Delta_i + [n/2] + 1) / n \\ (n * c_i - x_i - [n/2] + x_i + [n/2] + 1) / n \end{bmatrix} \quad (21)$$

Where  $[n/2]$  is the downward rounding of  $n/2$ , that is, when  $n=5$ , its value is.

The moving sine has a faster running speed in the microprocessor environment because of the recursive idea of replacing old and new elements, which is similar to the moving average. It is also more suitable for the case with unstable amplitude as shown in the figure below. It can accurately calculate a, b, c, amplitude A and initial phase of each point  $\theta$  (Figure 5).




Figure 5: Ultrasonic signals.

For an ultrasonic echo signal, after the amplitude  $A$  of each point is obtained by moving fitting, the amplitude envelope can be obtained, as shown in the dotted envelope in the below (Figure 6).




Figure 6: Ultrasound echo signal.

## Results

In large impedance measurements, the signal is extremely weak, so a differential circuit is introduced to change it into complex impedance form, and the simplicity of sine fitting in amplitude and phase calculation is used to assist in calculating the impedance magnitude, which plays an important role in subsequent large impedance measurements.

## Conflict of Interest

We have no conflict of interests to disclose, and the manuscript has been read and approved by all named authors.

## Acknowledgments

This work was supported by the Philosophical and Social Sciences Research Project of Hubei Education Department (19Y049), and the Staring Research Foundation for the Ph.D. of Hubei University of Technology (BSQD2019054), Hubei Province, China.

## References

- Sinclair A, Saeedi P, Kaundal A, Karuranga S, Malanda B, et al. (2020) Diabetes and global ageing among 65-99-year-old adults: Findings from the International Diabetes Federation Diabetes Atlas, (9<sup>th</sup> edn.), Diabetes Res Clin Pract 162: 108078.
- Peron EP, Ogbonna KC, Donohoe KL (2015) Antidiabetic medications and polypharmacy. Clin Geriatr Med 31(1): 17-27.
- Saito N, Toyoda M, Ono M, Kaneyama N, Kimura M, et al. (2020) Importance of the Evaluation of Renal Function for the Prevention of Hypoglycemia in Elderly Diabetes Patients. Tokai J Exp Clin Med 45(3): 139-143.
- Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, et al. (2014) Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med 174(2): 251-258.
- Lipska KJ, Ross JS, Wang Y, Inzucchi SE, Minges K, et al. (2014) National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med 174(7): 1116-1124.
- Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, et al. (2002) Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 25(3): 458-463.
- Connor OPJ, Ismail BF (2011) Near-Normalization of Glucose and Microvascular Diabetes Complications: Data from Accord and Advance. Ther Adv Endocrinol Metab 2(1): 17-26.
- American Diabetes Association (2021) 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care 44(Suppl 1): S73-S84.
- Hoogwerf BJ (2008) Action to Control Cardiovascular Risk in Diabetes Study Group. Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleve Clin J Med 75(10): 729-737.
- Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, et al. (2010) The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340: b4909.
- Chin MH, Drum ML, Jin L, Shook ME, Huang ES, et al. (2008) Variation in treatment preferences and care goals among older patients with diabetes and their physicians. Med Care 46(3): 275-286.
- Basu S, Shankar V, Yudkin JS (2016) Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis. Lancet Diabetes Endocrinol 4(11): 922-932.
- Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, et al. (2020) Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract 26(1): 107-139.
- Derek L, Geert JB, Susan SB, Felipe FC, Boris D, et al. (2019) Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 104(5): 1520-1574.
- Amir Q, Timothy JW, Devan K, Horwitch C, Barry MJ, et al. (2018) Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy for Nonpregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement Update from the American College of Physicians. Ann Intern Med 168: 569-576.



16. (2015) Type 2 diabetes in adults: Management: Guidance. Type 2 diabetes in adults: management.
17. Dunning T, Sinclair A, Colagiuri S (2014) New IDF guideline for managing type 2 diabetes in older people. *Diabetes Research and Clinical Practice* 103(3): 538-540.
18. Araki E, Goto A, Kondo T, Noda M, Noto H, et al. (2020) Japanese Clinical Practice Guideline for Diabetes 2019. *J Diabetes Investig* 11(4): 1020-1076.
19. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, et al. (2019) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *European Heart Journal* 41(2): 255-323.
20. Tschanz MP, Watts SA, Colburn JA, Conlin PR, Pogach LM (2017) Overview and Discussion of the 2017 VA/DoD Clinical Practice Guideline for the Management of Type 2 Diabetes Mellitus in Primary Care. *Fed Pract* 34(Suppl 8): S14-S19.
21. Bansal N, Dhaliwal R, Weinstock RS (2015) Management of diabetes in the elderly. *Med Clin North Am* 99(2): 351-377.
22. Sinclair A, Morley JE, Rodriguez ML, Paolisso G, Bayer T, et al. (2012) Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. *J Am Med Dir Assoc* 13(6): 497-502.
23. Diabetes Canada Clinical Practice Guidelines Expert Committee. (2018) Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. *Can J Diabetes* 42(Suppl 1): S1-S326.
24. Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. *N Engl J Med* 365(21): 2002-2012.
25. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, et al. (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). *Kidney Int* 63(1): 225-232.
26. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 359(15): 1577-1589.
27. Lipska KJ, Krumholz H, Soones T, Lee SJ (2016) Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults with Type 2 Diabetes. *JAMA* 315(10): 1034-1045.
28. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. (2008) Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 358(24): 2545-2559.
29. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. (2008) Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 358(24): 2560-2572.
30. Zoungas S, Patel A, Chalmers J, Galan BE, Li Q, et al. (2010) Severe hypoglycemia and risks of vascular events and death. *N Engl J Med* 363(15): 1410-1418.
31. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, et al. (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the Accord, Advance, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. *J Am Coll Cardiol* 53(3): 298-304.
32. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, et al. (2009) Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 360(2): 129-139.
33. Tran K, Reaven P (2020) Review of the veteran affairs diabetes trial: Lessons learned. *Rev Endocr Metab Disord* 21(4): 537-546.
34. Freeman J (2019) Management of hypoglycemia in older adults with type 2 diabetes. *Postgrad Med* 131(4): 241-250.
35. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, et al. (2001) Hypoglycemia in patients with type 2 diabetes mellitus. *Arch Intern Med* 161(13): 1653-1659.
36. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, et al. (2010) The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. *BMJ* 340: b5444.
37. Munshi MN, Slyne C, Segal AR, Saul N, Lyons C, et al. (2017) Liberating A1C goals in older adults may not protect against the risk of hypoglycemia. *J Diabetes Complications* 31(7): 1197-1199.
38. Pasciak WE, Berg DN, Cherlin E, Fried T, Lipska KJ (2021) Qualitative analysis of reasons for hospitalization for severe hypoglycemia among older adults with diabetes. *BMC Geriatr* 21(1): 318.
39. Yanase T, Yanagita I, Muta K, Nawata H (2018) Frailty in elderly diabetes patients. *Endocr J* 65(1): 1-11.
40. Kachroo S, Kawabata H, Colilla S, Shi L, Zhao Y, et al. (2015) Association between hypoglycemia and fall-related events in type 2 diabetes mellitus: analysis of a U.S. commercial database. *J Manag Care Spec Pharm* 21(3): 243-253.
41. Nelson JM, Dufraux K, Cook PF (2007) The relationship between glycemic control and falls in older adults. *J Am Geriatr Soc* 55(12): 2041-2044.
42. Chiba Y, Kimbara Y, Kodera R, Tsuboi Y, Sato K, et al. (2015) Risk factors associated with falls in elderly patients with type 2 diabetes. *J Diabetes Complications* 29(7): 898-902.
43. Schwartz AV, Vittinghoff E, Sellmeyer DE, Feingold KR, Reckoner N, et al. (2008) Diabetes-related complications, glycemic control, and falls in older adults. *Diabetes Care* 31(3): 391-396.
44. Orozco BD, Navarro PJ, Cebrián CAM, Guisasaola FA, Miana CE, et al. (2020) The influence of hemoglobin A1c levels on cardiovascular events and all-cause mortality in people with diabetes over 70 years of age. A prospective study. *Prim Care Diabetes* 14(6): 678-684.
45. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group *Lancet* 352(9131): 837-853.
46. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Emanuele NV, et al. (2015) Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 373(10): 978.
47. Vijan S, Sussman JB, Yudkin JS, Hayward RA (2014) Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. *JAMA Intern Med* 174(8): 1227-1234.
48. Nicolucci A, Pintauro B, Rossi MC, Messina R, Dotta F, et al. (2015) The social burden of hypoglycemia in the elderly. *Acta Diabetol* 52(4): 677-685.
49. Laiteerapong N, Cooper JM, Skandari MR, Clarke PM, Winn AN, et al. (2018) Individualized Glycemic Control for U.S. Adults with Type 2 Diabetes: A Cost-Effectiveness Analysis. *Ann Intern Med* 168(3): 170-178.
50. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, et al. (2010) Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. *Lancet* 375(9713): 481-489.
51. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ (2011) Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. *Diabetes Care* 34(6): 1329-1336.

52. Lega IC, Campitelli MA, Austin PC, Na Y, Zahedi A, et al. (2021) Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study. *Diabetologia* 64(5): 1093-1102.
53. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, et al. (2010) Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glyceemic treatment in the Accord trial. *Diabetes Care* 33(5): 983-990.
54. Mahoney GK, Henk HJ, McCoy RG (2019) Severe Hypoglycemia Attributable to Intensive Glucose-Lowering Therapy Among US Adults with Diabetes: Population-Based Modeling Study, 2011-2014. *Mayo Clin Proc* 94(9): 1731-1742.